- Home
- GDRX vs GH Comparison
GDRX vs GH Comparison
Compare GDRX & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDRX
- GH
- Stock Information
- Founded
- GDRX 2011
- GH 2011
- Country
- GDRX United States
- GH United States
- Employees
- GDRX N/A
- GH N/A
- Industry
- GDRX Retail: Computer Software & Peripheral Equipment
- GH Medical Specialities
- Sector
- GDRX Technology
- GH Health Care
- Exchange
- GDRX Nasdaq
- GH Nasdaq
- Market Cap
- GDRX 3.1B
- GH 3.0B
- IPO Year
- GDRX 2020
- GH 2018
- Fundamental
- Price
- GDRX $7.68
- GH $24.26
- Analyst Decision
- GDRX Buy
- GH Strong Buy
- Analyst Count
- GDRX 16
- GH 17
- Target Price
- GDRX $9.34
- GH $39.31
- AVG Volume (30 Days)
- GDRX 1.3M
- GH 2.4M
- Earning Date
- GDRX 11-07-2024
- GH 11-04-2024
- Dividend Yield
- GDRX N/A
- GH N/A
- EPS Growth
- GDRX N/A
- GH N/A
- EPS
- GDRX N/A
- GH N/A
- Revenue
- GDRX $775,092,000.00
- GH $643,810,000.00
- Revenue This Year
- GDRX $8.88
- GH $27.01
- Revenue Next Year
- GDRX $9.65
- GH $18.30
- P/E Ratio
- GDRX N/A
- GH N/A
- Revenue Growth
- GDRX 4.03
- GH 26.20
- 52 Week Low
- GDRX $4.14
- GH $15.81
- 52 Week High
- GDRX $9.26
- GH $37.04
- Technical
- Relative Strength Index (RSI)
- GDRX 47.78
- GH 42.60
- Support Level
- GDRX $7.34
- GH $24.55
- Resistance Level
- GDRX $7.82
- GH $27.13
- Average True Range (ATR)
- GDRX 0.33
- GH 1.28
- MACD
- GDRX -0.01
- GH 0.20
- Stochastic Oscillator
- GDRX 27.40
- GH 48.15
About GDRX GoodRx Holdings Inc.
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.